Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science gives a quick outline on why he feels T cell…
Browsing: Acute Lymphoblastic Leukemia
Anti-OX40 has been demonstrated to improve tumor free survival in mice and is now moving past the first Phase 1…
Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science gives an overview of the Phase 1 Study of Anti-OX40…
Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Alessandro M. Vannucchi discusses the…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Srdan Verstovsek discusses therapeutic insights…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Claire Harrison outlines her approach…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Hans Michael Kvasnicka discsuses myelofibrosis…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jaroslav Cermak discusses new opportunities…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Aristoteles Giagounidis discusses the optimal…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Norbert Gattermann discusses iron chelation…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Eva Hellström-Lindberg outlines her approach…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Austin G. Kulasekararaj discusses the…
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Martin Griesshammer outlines his view…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that circulating tumor…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher L. Hallemeier argues that observation…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Julio Garcia-Aguilar argues that observation without…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz discusses the difference in…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that immunotherapy is…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that TAS-102…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that EGFR…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg provides an update in…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update to…
Dr. Aly-Khan Lalani, MD highlights a study he presented at ESMO 2017 about the usefulness Neutrophil-to-lymphocyte ratio (NLR) and how…
Dr. Aly-Khan Lalani, MD gives an overview of the advancements in Kidney Cancer presented at ESMO 2017 including the Cabosun…
Dr. Aly-Khan A. Lalani, MD discusses the impact of Neutrophil-to-lymphocyte ratio (NLR) in mRCC and it’s effect on outcomes. BACKGROUND:…
During this segment from the Living Well series, Dr. Bart Scott, breaks down whats occurring at a cellular level with…
Although essential thrombocythemia (ET) is generally thought of as a disease that only affects the middle age and elderly population,…
The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive,…
In this Velocity Vlog activity, Dr. Howard L. Kaufman of the Rutgers Cancer Institute contextualizes updates to the standard of…
In this Velocity Vlog activity, Dr. Paul Nghiem of the University of Washington shares emerging data and expert analysis about…
The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive,…
Dr. Jack West reviews new evidence providing long-needed guidance on what patient surveillance after potentially curative surgery for early lung…
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data,…
How do you know if your MPN is progressing? Will it show in your blood work or will symptoms increase?…
Scott S. Tykodi MD of Seattle Cancer Care Alliance notes that the data from Checkmate 214 is clear that overall…
Michael Needle, MD and Chief Medical Officer for AVEO Oncology gives an update for the Phase 3 TIVO-3 trial, a…